April 21, 2018 10:41 PM ET

Biotechnology

Company Overview of Ardelyx, Inc.

Company Overview

Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company’s lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program f...

34175 Ardenwood Boulevard

Suite 200

Fremont, CA 94555

United States

Founded in 2007

75 Employees

Phone:

510-745-1700

Key Executives for Ardelyx, Inc.

President, CEO & Director
Age: 52
Total Annual Compensation: $520.0K
COO & Executive VP
Age: 45
Total Annual Compensation: $332.3K
Chief Medical Officer & Executive VP
Age: 51
Total Annual Compensation: $530.0K
Compensation as of Fiscal Year 2016.

Ardelyx, Inc. Key Developments

Ardelyx, Inc. Announces License Agreement with Knight Therapeutics, Inc. to Provides Knight with Exclusive Rights to Commercialize Tenapanor in Canada

Ardelyx, Inc. announced a license agreement with Knight Therapeutics, Inc. that provides Knight with exclusive rights to commercialize tenapanor in Canada. Tenapanor is Ardelyx's oral, first-in-class small molecule treatment that has completed Phase 3 development for irritable bowel syndrome with constipation (IBS-C) and is being evaluated in a second Phase 3 study for hyperphosphatemia. Under the terms of the agreement, Ardelyx is eligible to receive up to CAD 25 million in total payments including an upfront payment and development and sales milestones, as well as double-digit tiered royalties on net sales. Knight will have the exclusive rights to market and sell tenapanor in Canada.

Ardelyx, Inc. Presents at DCAT Week 2018, Mar-19-2018

Ardelyx, Inc. Presents at DCAT Week 2018, Mar-19-2018 . Venue: New York, New York, United States. Speakers: James Kanter.

Ardelyx, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended Dec. 31, 2017; Provides Pipeline Updates

Ardelyx, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended Dec. 31, 2017. For the quarter, the company reported licensing revenue of $42,000,000. Income from operations $10,962,000 compared to loss of $31,476,000 a year ago. Net income of $10,114,000 or $0.21 per basic and diluted share compared to loss of $31,276,000 or $0.66 per basic and diluted share a year ago. For the year, the company reported licensing revenue of $42,000,000. Loss from operations $65,115,000 compared to $112,895,000 a year ago. Net loss of $64,339,000 or $1.36 per basic and diluted share compared to $112,387,000 or $2.80 per basic and diluted share a year ago. Ardelyx, Inc. provided pipeline updates. Second Phase 3 Clinical Trial of Tenapanor for Hyperphosphatemia Underway: In February 2018, Ardelyx began treating patients in the Phreedom Trial, the company's second Phase 3 clinical trial of tenapanor for the treatment of hyperphosphatemia in patients with end-stage renal disease who are on dialysis. This clinical trial includes a 26-week open-label treatment period, with a 12-week placebo-controlled randomized withdrawal period followed by an additional 14-week safety extension period for a total of up to 52 weeks. An active control group, for safety analysis only and consistent with other Phase 3 registration studies for hyperphosphatemia, will receive sevelamer carbonate, open-label, for the entire 52-week study period. Topline data from this clinical trial are currently anticipated in 2019. Expanding Renal Pipeline with RDX013 Program: Ardelyx is leveraging its expertise in renal drug development to advance its early-stage RDX013 program for the potential treatment of hyperkalemia. RDX013 is a novel, small molecule program that Ardelyx believes may work by tapping into the gastrointestinal tract's natural ability to secrete potassium into the lumen of the gut to reduce serum potassium levels. This mechanism differs significantly from the potassium binders currently on or approaching the market, and, like tenapanor for hyperphosphatemia, has the potential to provide the first non-binder approach to treat hyperkalemia with the aim of improving adherence and compliance with potentially better efficacy and safety. Preparing NDA Submission for Tenapanor for IBS-C: Ardelyx has completed its T3MPO program designed to support the registration of tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). Both the T3MPO-1 and T3MPO-2 Phase 3 clinical trials achieved their primary endpoints and demonstrated that tenapanor had a durable effect on reducing constipation and abdominal pain caused by IBS-C, in many patients treated. The favorable safety profile of tenapanor was supported by the completed T3MPO-3 long-term, safety extension study. With the completion of clinical development for this program, Ardelyx is preparing a New Drug Application for tenapanor for IBS-C, which the company currently intends to submit to the U.S. Food and Drug Administration in the second half of 2018.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ardelyx, Inc., please visit www.ardelyx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.